Vir Biotechnology is a clinical-stage biotechnology company that develops treatments for infectious diseases. The company's platform uses monoclonal antibodies to target and neutralize viruses, including COVID-19, HIV, and hepatitis B. Vir's technology has the potential to improve patient outcomes and reduce healthcare costs by providing effective treatments for viral infections. The company was founded in 2016 and is headquartered in San Francisco, California.